Early Parkinson's Disease is when the brain slowly stops controlling movement well. This study is looking at a medicine called NEU-411 to see if it helps people with a special type of Parkinson's where a gene called LRRK2 is too active. A DNA test will help find people with this special type. The study will see if NEU-411 is safe and works well.
People who join will either take NEU-411 or a placebo (a pill that does nothing) every day for 52 weeks. Around 150 people will join, and they will be randomly picked to get the real medicine or the placebo. A follow-up visit will happen two weeks after the last dose.
- Participants must be aged 50-80 and have early Parkinson's.
- They need a genetic test showing LRRK2 activity.
- The study lasts about a year with regular medicine intake.
People with other serious health issues or different types of Parkinson's cannot join. Full details are in the study protocol.
How understandable was the trial content above?
Hard to understand
Easy to understand